Health Condition 1: null- COPD
Conditions
Interventions
Intervention1: Doxycycline.: It is an antibiotic,available in the market for last 30 yrs.It is orally used,100mg tablet or capsule twice daily after taking food.For this study duration of therapy is o
Sponsors
Dr Parthasarathi Bhattacharyya
Institute of Pulmocare Research
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria i) Male or female adult aged more than equal 40 years years who has signed an written informed consent form prior to initiation of any study and related procedure ii) Patients of severe to very severe COPD according to the GOLD guideline criteria 2008. The COPD being diagnosed as FEV1/FVC less than 70 %, FEV1 less than 80 %, and pre bronchodilator FEV1 being essentially below 50% of predicted.
Exclusion criteria
Exclusion criteria: i) Age less than 40 years and more than 75 years ii) Unwillingly for informed written consent iii) H/o doxycycline intolerance iv) Very sick patient likely unable to perform the spirometry and comply to the required follow up protocol. v) Patients who, in the judgment of the investigator, have a clinically significant co-morbidity, or laboratory abnormality ? that can affect the spirometric performance or the overall symptomatology, or can increase the risk of morbidity if enrolled in the protocol (viz, unstable angina, recent MI) vi) Patient with concomitant pulmonary disease, e.g. (active pulmonary tuberculosis, clinically significant bronchiectasis, sarcoidosis, interstitial lung disease etc. vii) Pregnancy and lactation and women with child bearing potential viii) Exacerbation in last 4 weeks requiring antibiotics and/or steroid ix) History of hospitalization for any reason within last 4 weeks of screening x) Patients with lung lobectomy, lung volume reduction or lung transplantation done in past xi) Any vaccination (flu or pneumococcal) within two days of randomization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in FEV1 in terms of no reduction or improvement in doxycycline treated COPD patients compared to the standard treatment.Timepoint: One year | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Not Applicable | — |
Countries
India
Contacts
Public ContactDr Parthasarathi Bhattacharyya
Consultant
Outcome results
None listed